• / Free eNewsletters & Magazine
  • / My Account
Home>Investing Topics>Convertibles

Convertibles

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Molina Healthcare Announces Proposed Offering of $330 Million of Senior Notes Due 2025

    Molina Healthcare Announces Proposed Offering of $330 Million of Senior Notes Due 2025

  2. Molina Healthcare Announces Pricing of Offering of $330 Million of Senior Notes Due 2025

    Molina Healthcare Announces Pricing of Offering of $330 Million of Senior Notes Due 2025

  3. First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1525 Per Share for June

    First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution of $0.1525 Per Share for June

  4. Reviva Pharmaceuticals Announces Closing of Bridge Financing and Addition of a New Member to Its Board of Directors

    Reviva Pharmaceuticals Announces Closing of Bridge Financing and Addition of a New Member to Its Board of Directors

  5. Renesas Electronics Announces Secondary Offering of Shares

    Renesas Electronics Announces Secondary Offering of Shares

  6. Rexnord Reports Q4 FY17 Financial Results and Initiates FY18 Operating Outlook

    Rexnord Reports Q4 FY17 Financial Results and Initiates FY18 Operating Outlook

  7. New Manager Off to Good Start at Popular Dividend Fund

    John Linehan, manager of the Bronze-rated  T. Rowe Price Equity Income, has generated fine results since taking over for the retiring Brian Rogers in late 2015. 

  8. DexCom Prices Offering of $350 Million of 0.75% Convertible Senior Notes

    DexCom Prices Offering of $350 Million of 0.75% Convertible Senior Notes

  9. NOXXON Pharma Secures a Private Placement of €1 Million and Additional Financing of up to €10 Million Through Convertible Notes with Share Subscription Warrants Attached to Finance Further Clinical ...

    NOXXON Pharma Secures a Private Placement of €1 Million and Additional Financing of up to €10 Million Through Convertible Notes with Share Subscription Warrants Attached to Finance Further Clinical Development of NOX-A12

  10. NOXXON Pharma N.V. Reports 2016 Financial Results & Announces Advanced Discussions Regarding a Convertible Bond Financing

    NOXXON Pharma N.V. Reports 2016 Financial Results & Announces Advanced Discussions Regarding a Convertible Bond Financing

12345

©2017 Morningstar Advisor. All right reserved.